Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 1,308.0	$ 1,204.9
Marketable securities	2,120.5	640.5
Accounts receivable, net	1,227.0	1,292.4
Due from unconsolidated joint business, net	314.5	283.4
Inventory	893.4	804.0
Other current assets	836.9	309.8
Total current assets	6,700.3	4,535.0
Marketable securities	2,760.4	1,470.7
Property, plant and equipment, net	2,187.6	1,765.7
Intangible assets, net	4,085.1	4,028.5
Goodwill	2,663.8	1,760.2
Investments and other assets	1,107.6	754.6
Total assets	19,504.8	14,314.7
Current liabilities:
Current portion of notes payable and other financing arrangements	4.8	3.1
Taxes payable	208.7	168.1
Accounts payable	267.4	229.2
Accrued expenses and other	2,096.8	1,817.7
Total current liabilities	2,577.7	2,218.1
Notes payable and other financing arrangements	6,521.5	580.3
Long-term deferred tax liability	124.9	52.2
Other long-term liabilities	905.8	650.1
Total liabilities	$ 10,129.9	$ 3,500.7
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	$ 0.0	$ 0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	0.0	4,196.2
Accumulated other comprehensive loss	(224.0)	(59.5)
Retained earnings	12,208.4	9,283.9
Treasury stock, at cost; 22.6 million shares, respectively	(2,611.7)	(2,611.7)
Total Biogen Inc. shareholders’ equity	9,372.8	10,809.0
Noncontrolling interests	2.1	5.0
Total equity	9,374.9	10,814.0
Total liabilities and equity	$ 19,504.8	$ 14,314.7